SLC5A2 and type 2 diabetes mellitus: Since 2015, when the EMPA-REG OUTCOME trial was first published, data have accumulated showing that in people with and without type 2 diabetes and chronic kidney disease, treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors results in reduced cardiovascular risk (HR: 0.76; [95% CI: 0.72–0.79]) and risk of a primary renal outcome (HR: 0.69; [95% CI: 0.61–0.79]) [4].